{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-24-000059","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2024-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.783768+00:00","generated_at":"2026-06-01T16:17:31.010728+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Autolus reports Q1 2024 net loss of $52.7M; cash $758.5M; obe-cel PDUFA Nov 16","bullets":["Net loss $52.7M ($0.24 diluted EPS) vs $39.8M loss year ago; license revenue $10.1M.","Cash $758.5M at March 31, 2024, up from $239.6M Dec 31, after $350M offering and BioNTech financing.","Obe-cel BLA under FDA review; PDUFA target action date Nov 16, 2024; MAA accepted by EMA.","First two patients enrolled in SLE Phase 1 (CARLYSLE); initial data expected end of 2024.","BioNTech strategic collaboration ($50M upfront, up to $582M milestones) and $200M private placement; Mike Bonney appointed Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-24-000059","json":"https://secwatch.observer/filing/0001730463-24-000059.json","markdown":"https://secwatch.observer/filing/0001730463-24-000059.md","text":"https://secwatch.observer/filing/0001730463-24-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000059/0001730463-24-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000059/autl-20240517.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T16:17:31.010728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7d643f9f993a2dd0f78522223cc60f0779768b0","claim":"Autolus Therapeutics plc reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its operational and financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000059/0001730463-24-000059-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}